The first-generation anti-EGFR small-molecule tyrosine kinase inhibitor (TKI) erlotinib demonstrated minimal but statistically significant improved overall survival (OS) in combination with gemcitabine vs. gemcitabine alone as a first-line treatment of patients with advanced PDA (6.2 vs. 5.9 months, HR = 0.82, p = 0.03) [9]. Here, EGFR is linked to Patent ductus arteriosus.